Holen Sie sich die Stockscreener-App
9.94
3.21%
-0.33
Schlusskurs vom Vortag:
$10.27
Offen:
$10.29
24-Stunden-Volumen:
593.88K
Relative Volume:
0.73
Marktkapitalisierung:
$590.27M
Einnahmen:
$122.29M
Nettoeinkommen (Verlust:
$122.31M
KGV:
4.6149
EPS:
2.1539
Netto-Cashflow:
$12.00M
1W Leistung:
-12.73%
1M Leistung:
-15.76%
6M Leistung:
-4.42%
1J Leistung:
-12.65%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$9.885
$11.33
52-Wochen-Spanne:
$8.01
$15.04
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Firmenname
Zevra Therapeutics Inc
Sektor
Branche
Telefon
(888) 958-1253
Adresse
101 FEDERAL STREET, BOSTON
Compare ZVRA vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
9.94 | 590.27M | 122.29M | 122.31M | 12.00M | 2.1539 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Eingeleitet | BTIG Research | Buy |
| 2025-07-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-08 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Eingeleitet | Guggenheim | Buy |
| 2024-09-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-24 | Bestätigt | Maxim Group | Buy |
| 2024-04-02 | Bestätigt | Maxim Group | Buy |
| 2024-03-12 | Eingeleitet | William Blair | Outperform |
| 2023-03-17 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Form 4 Zevra Therapeutics Inc: Neil F. McFarlane (Director, President and CEO) For: 10 October - Investing.com Canada
Zevra Therapeutics president and CEO sells $224,948 in stock - Investing.com
A 20,000-share sale was reported by Zevra Therapeutics (ZVRA) director Neil F. McFarlane. - Stock Titan
Diluted net income available to common stockholders of Zevra Therapeutics, Inc. – HAN:1GDA - TradingView
Zevra Therapeutics, Inc. Stock (ZVRA)Quote Nasdaq - marketscreener.com
Zevra Therapeutics at Cantor conference: growth, cash and rare-disease bets - Investing.com India
ZVRA: Expanding rare disease reach with strong financials, robust IP, and accelerating global growth - TradingView
Zevra Therapeutics at Cantor conference: growth, cash and rare-disease bets - Investing.com Canada
Why (ZVRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Zevra Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance
Zevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual Symposium - Quiver Quantitative
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium - Barchart.com
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium - The Manila Times
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Four new Zevra employees receive stock options that vest over four years - Stock Titan
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy By Investing.com - Investing.com Canada
ZVRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy - Investing.com
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics Insider Sold Shares Worth $474,774, According to a Recent SEC Filing - marketscreener.com
Zevra Therapeutics (ZVRA) insider sells 42,666 shares - Stock Titan
Zevra Therapeutics Insider Sold Shares Worth $474,774, According to a Recent SEC Filing - Yahoo Finance
Price-Driven Insight from (ZVRA) for Rule-Based Strategy - Stock Traders Daily
Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker - Stock Titan
Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position - Stock Titan
ZVRA Q2 2026 Earnings: EPS Beats Estimates by 27.85% as Bottom-Line Strength ContinuesLow Estimate Range - vinanet.vn
Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA - TradingView
Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc.ZVRA - PR Newswire
Canaccord Genuity Sticks to Its Buy Rating for Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock - MarketBeat
Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com Nigeria
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics - The National Law Review
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com UK
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therape - The National Law Review
Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
HC Wainwright Has Positive Outlook for ZVRA FY2027 Earnings - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Reach Out - ACCESS Newswire
Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data - Sahm
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zevra Therapeutics, Inc. (ZVRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Zevra Therapeutics, Inc. (ZVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
ZVRA Maintained by Guggenheim -- Price Target Lowered to $23.00 - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Lowered to $23.00 at Guggenheim - MarketBeat
Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zevra Therapeutics Inc-Aktie (ZVRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| NEIL F MCFARLANE | Director |
Oct 12 '26 |
Proposed Sale |
11.39 |
20,000 |
227,800 |
0 |
| RAHSAAN THOMPSON | Officer |
Aug 14 '26 |
Proposed Sale |
11.18 |
42,666 |
477,006 |
0 |
| Thompson Rahsaan | Chief Legal & Compliance |
Aug 14 '26 |
Sale |
11.13 |
42,666 |
474,774 |
37,569 |
| Watton Corey Michael | Director |
Aug 10 '26 |
Option Exercise |
4.97 |
12,300 |
61,131 |
14,100 |
| Watton Corey Michael | Director |
Aug 10 '26 |
Sale |
11.25 |
12,300 |
138,377 |
1,800 |
| JOHN BODE | Director |
Jul 08 '26 |
Proposed Sale |
14.85 |
10,516 |
156,163 |
0 |
| Thompson Rahsaan | Chief Legal & Compliance |
Jun 22 '26 |
Sale |
12.68 |
34,557 |
438,304 |
80,235 |
| Rahsaan Thompson | Officer |
May 11 '26 |
Proposed Sale |
11.13 |
36,351 |
404,587 |
0 |
| Thompson Rahsaan | Chief Legal & Compliance |
May 11 '26 |
Sale |
11.30 |
1,794 |
20,272 |
48,125 |
| Bode John B | Director |
Mar 24 '26 |
Option Exercise |
4.93 |
78,400 |
386,512 |
123,400 |
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):